Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FF-31501 is an autologous synovial mesenchymal stem cell (MSC) therapy developed for the treatment of meniscus tears in the knee. The therapy uses human synovial MSCs collected from the patient and is administered via arthroscopic injection with the aim of promoting regeneration of the meniscus tissue, improving knee function, and reducing symptoms and pain. Its mechanism includes cartilage, cell, and tissue replacement via the engraftment and regenerative signaling of synovial MSCs. FF-31501 is being developed by FUJIFILM Corporation, including FUJIFILM Toyama Chemical, in collaboration with Tokyo Medical and Dental University. It is currently under investigation in a phase 3 clinical trial for meniscus injuries requiring meniscectomy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FF-31501.